Stoke Therapeutics Is An Early Stage Biopharmaceutical Company Founded In 2014 And Based In Bedfordmassachusettswith Additional Offices In Cambridgethe Company Became Publicly Traded In June 2019 Under The Ticker Symbol Stokstoke Is Focused On Developing Rna Based Medicines To Address Severe Genetic Diseases By Upregulating Protein Expression The Company Utilizes Its Proprietary Tango Platform To Create Antisense Oligonucleotidesasosthat Selectively Restore Protein Levelsits Lead Clinical Candidatestk 001Is In Phase I Ii Trials For Dravet Syndromea Severe Genetic Epilepsyother Candidates Include Stk 002Which Is In Preclinical Development For Autosomal Dominant Optic Atrophyand Zorevunersendeveloped In Collaboration With Biogen For Dravet Syndromestoke Also Partners With Acadia Pharmaceuticals To Discover And Develop Novel Rna Based Medicines Targeting Genetic Neurodevelopmental Diseases
